Loading
A phase 1/2 trial of Brenetafusp, Pembrolizumab, Tebentafusp and Bevacizumab in advanced solid tumours, run by Immunocore Ltd, active and no longer recruiting.
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors is a phase 1/2 interventional study registered as NCT04262466 by Immunocore Ltd, with 410 participants enrolled, started 2020-02-25 and due to reach its primary completion in 2026-10. Interventions recorded: Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp and Brenetafusp and bevacizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Immunocore, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/